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Abstract
Ezetimibe is a selective cholesterol absorption inhibitor with an excellent side-
effect profile, able to reduce low-density lipoprotein (LDL) cholesterol by 15-25%
from baseline in monotherapy and on top of statins and fibrates. Yet, it seems
that ezetimibe produces quantitative rather than qualitative changes in LDL,
with small net effects on atherogenic dyslipidaemia. This is supported by findings
from the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances
Atherosclerosis Regression (ENHANCE) study on atherosclerosis progression,
where the addition of ezetimibe to simvastatin in patients with heterozygous
familial hypercholesterolaemia did not affect the mean change in carotid intima-
media thickness, although a significant reduction in LDL cholesterol levels was
observed. The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study has
further shown that combination treatment with simvastatin significantly reduced
LDL cholesterol levels in patients with aortic stenosis, but did not affect the
primary end point of aortic valve and cardiovascular events, although
a significant reduction in the risk of ischaemic events was reported. Formal
cardiovascular outcome trials are underway and these will provide additional
insights into the long-term effects of ezetimibe on clinical events as well as on
atherogenic dyslipidaemia, beyond LDL cholesterol levels.
K Ke ey y   w wo or rd ds s: :   ezetimibe, cardiovascular risk, atherosclerosis, dyslipidaemia.
Ezetimibe represents the first of a new class of agents, the cholesterol
absorption  inhibitors,  able  to  reduce  low-density  lipoprotein  (LDL)
cholesterol by 15-25% from baseline in monotherapy and on top of statins
and fibrates [1]. The combination with simvastatin represents the most
common combined therapy, due to the fact that ezetimibe can add an
extra 20% reduction in LDL cholesterol to that seen with statins alone [2].
Also, ezetimibe is proved to be effective in conditions associated with
dyslipidaemia [3-6].
Yet,  it  seems  that  ezetimibe  produces  quantitative  rather  than
qualitative  changes  in  LDL,  with  small  net  effects  on  atherogenic
dyslipidaemia. This is supported by findings from the Ezetimibe and
Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression
(ENHANCE) study on atherosclerosis progression, where the addition of
ezetimibe  to  simvastatin  in  patients  with  heterozygous  familial
hypercholesterolaemia did not affect the mean change in carotid intima-
media thickness, although a significant reduction in LDL cholesterol levels
was observed [7]. The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS)
study [8] has further shown that combination treatment with simvastatin
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significantly  reduced  LDL  cholesterol  levels  in
patients with aortic stenosis, but did not affect the
primary end point of aortic valve and cardiovascular
events, although a significant reduction in the risk
of ischaemic events was reported.
Since these negative findings were obtained
despite a significant reduction in LDL cholesterol
levels, we have recently suggested that ezetimibe
treats mainly LDL cholesterol and not the underlying
dyslipidaemia  [9].  In  fact,  several  sources  of
evidence suggest that the “quality” rather than only
the “quantity” of LDL exerts a direct influence 
on  cardiovascular  risk:  LDL  comprise  multiple
distinct subclasses that differ in size, density,
physicochemical composition, metabolic behaviour
and atherogenicity [10, 11]. We have recently shown
that small, dense LDL are associated with a greater
cardiovascular risk [12, 13]. 
Few studies have so far assessed the effects of
ezetimibe on LDL size or their subclass distribution
in patients with hypercholesterolaemia, and those
in monotherapy are summarized in Table I. Overall,
ezetimibe  showed  a limited  role  in  reducing
atherogenic small, dense LDL; yet, since most 
of these trials included patients at higher car  dio  -
vascular risk (due to the concomitant presence of
obesity, diabetes and the metabolic syndrome), it
cannot  be  fully  excluded  that  this  may  have
affected the results of these studies.
Therefore, available data so far suggest that
treatment with ezetimibe, as monotherapy or in
combination with simvastatin, significantly reduces
LDL cholesterol concentrations but can be asso  -
ciated with the development of a pro-atherogenic
LDL subclass profile. This is directly linked to the
observation that end-point studies so far have
consistently failed to show that the LDL-lower  ing
effect of ezetimibe directly transfers into a cor  -
responding reduction in cardiovascular events.
Further,  it  has  recently  been  highlighted  that
ezetimibe and its combination with simvastatin still
generate 4 billion dollars per year with no evidence
of clinical benefit [14].
Future prospective studies are needed to clarify
to  what  extent  ezetimibe  is  able  to  reduce
atherogenic dyslipidaemia, beyond LDL cholesterol
levels. Formal cardiovascular outcome trials are
underway and these will provide additional insights
into the long-term effects of ezetimibe. For instance,
the effect of the combination with statins compared
to statin monotherapy on cardiovascular end points
is  currently  being  examined  by  the  Improved
Reduction of Outcomes: Vytorin Efficacy In  ter  -
national Trial (IMPROVE-IT), which aims to recruit
a very large cohort of patients with acute coronary
syndromes with a follow-up period of at least 
2.5 years [15].
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